FINWIRES · TerminalLIVE
FINWIRES

中國股市小漲,央行維持關鍵利率不變;北方稀土、海康威視股價因第一季業績而上漲。

-- 週一,中國股市小幅上漲,此前中國央行維持基準利率不變並發布了新的市場規則。 衡量中國股市的主要指標-上證綜合指數上漲0.8%,或30.70點,收在4082.13點。深證成指上漲0.6%,或81.33點,收在14966.75點。 中國人民銀行連續第11個月維持基準利率不變。央行將一年期貸款市場報價利率(LPR)維持在3%,五年期及以上期限的LPR維持在3.5%。 荷蘭國際集團(ING)分析師預計LPR不會發生變化,因為第一季國內生產毛額(GDP)成長率仍維持在4.5%至5%的年度目標區間內。 同時,路透社週一報道稱,中國3月稀土磁鐵出口量為5,238噸,年減1.6%,但環比成長11%。 路透社當日報道稱,儘管美方宣布扣押了一艘試圖繞過封鎖的伊朗貨船,引發了人們對停火協議可能難以維持的擔憂,但投資者仍然對美伊達成協議抱有希望。 公司新聞方面,北方稀土(SHA:600111)公佈第一季業績預期後,股價上漲3%。預計其歸屬於股東的淨利將年增109%至118%,達到9億元至9.4億元。 杭州海康威視數位技術(SHE:002415)股價上漲4%,該公司第一季淨利年增36%,達到27.8億元。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703